This project investigates a focused library of 30 novel chalcone derivatives as innovative antimitotic agents. Expanding on previous data establishing their cytotoxic and antimitotic activity, this study highlights three top lead compounds. The study aims to determine their anticancer breadth across diverse tumor lines and establish safety windows using non-tumor human cells. Crucially, the project will identify their molecular target interaction at the tubulin colchicine-binding site using biochemical competition assays. Furthermore, the compounds will be evaluated for their capability to inhibit P-glycoprotein mediated efflux, reversing multidrug resistance phenotypes. Finally, combination studies with paclitaxel will be performed to establish synergistic therapeutic regimens. project will help establish the therapeutic potential of selective lead candidates tailored for resistant oncological targets.
This project investigates a focused library of 30 novel chalcone derivatives as innovative antimitotic agents. Expanding on previous data establishing their cytotoxic and antimitotic activity, this study highlights three top lead compounds. The study aims to determine their anticancer breadth across diverse tumor lines and establish safety windows using non-tumor human cells. Crucially, the project will identify their molecular target interaction at the tubulin colchicine-binding site using biochemical competition assays. Furthermore, the compounds will be evaluated for their capability to inhibit P-glycoprotein mediated efflux, reversing multidrug resistance phenotypes. Finally, combination studies with paclitaxel will be performed to establish synergistic therapeutic regimens. project will help establish the therapeutic potential of selective lead candidates tailored for resistant oncological targets.
Project area: